ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Rational application of gefitinib in NSCLC patients with sensitive EGFR mutations based on pharmacokinetics and metabolomics

Feng, Wei; Chen, Xi; Guan, Shao-xing; Ruan, Hong-lian; Huang, Yan; Zhang, Hui-zhen; Yang, Yun-peng; Fang, Wen-feng; Zhao, Hong-yun; Zhuang, Wei; Xin, Shuang; Chen, You-hao; Wang, Fei; Gao, Yue; Huang, Min*; Wang, Xue-ding*; Zhang, Li*广州医学院; 广州中医药大学; 中山大学
Acta Pharmacologica Sinica2022-7DOI: 10.1038/s41401-021-00791-5
2被引8阅读
引用收藏
分享

摘要

Gefitinib has been available in the market for 20 years, but its pharmacokinetic mechanism of response is little known. In this study, we examined the pharmacokinetic and metabolomic profiles in non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutations. A total of 216 advanced NSCLC patients were enrolled, and administered gefitinib at the standard dosage of 250 mg/day, which was established in heterogeneous subjects with non-sensitive mutations. We identified and quantified three main metabolites (named as M1, M2 and M3) in the plasma of patients, the correlations between the concentration of gefitinib/metabolites and efficacy were analyzed. In exploratory and validation set, gefitinib concentration was not correlated with clinical effects. Considering the result that the therapeutic effects of 250 mg/2-day was better than that of 250 mg/day in a multiple center clinical trial, the standard dose might be higher than that for maximal efficacy according to the hypothetical dose-response curve. Among the three metabolites, the IC50 of M2 in HCC827 and PC9 cell lines was significantly lower, and Conc.(brain)/Conc.(plasma) of M2 in mice was significantly higher than those of gefitinib, suggesting its higher potential to penetrate blood-brain barrier and might be more effective in the treatment of brain metastatic tumor than gefitinib. Consistently and attractively, higher M2 plasma concentration was found to be correlated with better clinical outcome in patients with brain metastases (the median PFS of C-M2 < 12 ng/mL and C-M2 >= 12 ng/mL were 17.0 and 27.1 months, respectively, P = 0.038). The plasma concentration of M2 >= 12 ng/mL was a strong predictor of the PFS of NSCLC patients. In conclusion, for NSCLC patients with EGFR sensitive mutations, the standard dose is suspectable and could be decreased reasonably. M2 plays an important role in efficacy and may be more effective in the treatment of metastatic tumor than gefitinib.

学科与关键词

关键词
gefitinibNSCLCEGFR mutationspharmacokineticsmetabolomics
相关
加载中…
  • Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non-Small-Cell Lung Cancer
    Zhou Qing; Zhang Xu Chao; Chen Zhi Hong; Yin Xiao Lu; Yang Jin Ji; Xu Chong Rui; Yan Hong Hong; Chen Hua Jun; Su Jian; Zhong Wen Zhao; Yang Xue Ning; An She Juan; Wang Bin Chao; Huang Yi Sheng; Wang Zhen; Wu Yi Long*Journal of Clinical Oncology, 2011, 29(24): 3316-3321.被引 80
  • Gefitinib plus chemotherapy versus gefitinib alone in untreated patients with EGFRmutated non-small cell lung cancer and brain metastases (GAP Brain): An open-label, randomized, multicenter, phase 3 study.
    Chen, Likun; Hou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Zhang, Baishen; Chen, Jing; You, ZhixuanAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 1
  • Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study
    Hou, Xue; Li, Meichen; Wu, Guowu; Feng, Weineng; Su, Jin; Jiang, Honghua; Jiang, Guanming; Chen, Jing; Zhang, Baishen; You, Zhixuan; Liu, Qing; Chen, Likun*JAMA Network Open, 2023, 6(2): e2255050.被引 4
查看全部 →

发表信息

论文状态
公开发表
期刊
Acta Pharmacologica Sinica
发表日期
2022-07
卷期
第 43 卷, 第 7 期
页码
1857-1864
DOI
10.1038/s41401-021-00791-5
语言
ENGLISH
期刊收录
CSCD-C.CAST-P
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973398, 81473283, 81730103, 81573507, 82020108031]; National Key Research and Development Program [2017YFC0909300, 2016YFC0905000]; Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030]; Science and Technology Program of Guangzhou [201607020031]; National Engineering and Technology Research Center for New Drug Druggability Evaluation (Seed Program of Guangdong Province) [2017B090903004]; 111 project [B16047]; China Postdoctoral Science Foundation [2019M66324, 2020M683140, 2020M683139]

作者

  • F

    Feng, Wei (第一作者)

    sun yat sen univ

  • C

    Chen, Xi

    sun yat sen univ

查看全部 17 位作者收起作者
  • G

    Guan, Shao-xing

    sun yat sen univ

  • R

    Ruan, Hong-lian

    guangzhou med univ

  • H

    Huang, Yan

    sun yat sen univ

  • Z

    Zhang, Hui-zhen

    sun yat sen univ

  • Y

    Yang, Yun-peng

    sun yat sen univ

  • F

    Fang, Wen-feng

    sun yat sen univ

  • Z

    Zhao, Hong-yun

    sun yat sen univ

  • Z

    Zhuang, Wei

    sun yat sen univ

  • X

    Xin, Shuang

    sun yat sen univ

  • C

    Chen, You-hao

    sun yat sen univ

  • W

    Wang, Fei

    2 · guangzhou univ chinese med

  • G

    Gao, Yue

    sun yat sen univ

  • H

    Huang, Min (通讯)

    sun yat sen univ

  • W

    Wang, Xue-ding (通讯)

    sun yat sen univ

  • Z

    Zhang, Li (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417